

# Department of Radiation Oncology

## Monthly Research Update: December 2022

### Who Owns Research Data?

#### DECEMBER AT A GLANCE TOTALS

<b>Clinical trials</b>	
Total enrolled	28
GCC, other	1
NRG, NCI, co-ops	4
PCG Registry	23
<b>Grants and contracts</b>	
New awards	2
Submitted	1
<b>Articles published</b>	9

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at [msegers@som.umaryland.edu](mailto:msegers@som.umaryland.edu). The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at [nknight@umm.edu](mailto:nknight@umm.edu)

Research in the Department of Radiation Oncology is conducted through the University of Maryland School of Medicine under the rules, regulations, and policies of the University of Maryland Baltimore (UMB). With only a few exceptions, all research activities, including grants, contracts, and other agreements, are managed by UMB, and related work must be compliant and consistent with UMB policies. Researchers should be familiar with these policies. Of special note is the [UMB Policy Regarding Ownership, Management, and Sharing of Research Data](#) (IV-99.01(A)). In addition to addressing varying needs in an increasingly complex environment of federal, state, and sponsor-specific requirements for research data, the policy was developed because the “increased mobility of university researchers in recent years has changed the continuity of scientific research, necessitating the development of institutional policies on data access, retention, and transfer.” This policy applies to all data that result from research activity performed at or under the auspices of UMB, regardless of funding source, and applies to all faculty, staff, postdoctoral fellows, students, visitors, and others (including consultants) involved in the design, conduct, or reporting of research.

The policy defines research data, which can take many forms, and briefly addresses key issues, including: (1) ownership of data, “UMB owns all research data”; and (2) PI data rights, “Anyone who leaves UMB may request to take copies (but not originals) of Research Data created by or on his/her behalf. However, no copies of research data may be taken, unless prior written approval is granted by the Dean or designee. In no event may anyone take originals of research data.” Other policies on the site address intellectual property restrictions, classified and proprietary work, and data retention/archival policies. Every researcher should be familiar with these policies and updates to ensure that the department’s work remains compliant and to avoid unwelcome surprises during regular audits or reviews.

*Notes that as of January 25, new federal policies will go into effect requiring specific plans for data sharing of results from studies funded by NIH. UMB/UMSOM have developed guidelines for data sharing that remain compatible with existing institutional policy. These will be covered in the January Monthly Research Update.*

### Clinical Trial Enrollment

- 23 patients were enrolled at MPTC on the **PCG Registry**
- 2 patients were enrolled at MPTC on the **Deep Thermal Therapy HUD**
- 1 patient was enrolled at MPTC on **GCC 20110**: A single-arm, single-stage phase II trial of selective avoidance of nodal volumes at minimal Risk (SAVER) in the contralateral neck of patients with p16-positive oropharynx cancer
- 1 patient was enrolled at MPTC on **EAF151**: Change in relative cerebral blood volume as a biomarker for early response to bevacizumab in patients with recurrent glioblastoma
- 1 patient was enrolled at UMMC on **NRG HN009**: Randomized phase II/III trial of radiation with high-dose cisplatin (100 mg/m<sup>2</sup>) every 3 weeks versus radiation with low-dose weekly cisplatin (40 mg/m<sup>2</sup>) for patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN)

## Grants and Contracts

### Funded:

- **Erika Davies, PhD**, PureTech LYT 100, Inc., for “Pharmacokinetic (PK) study of LYT-100 (12/22–6/23)” (\$78,800).
- **Phuoc T. Tran, MD, PhD, contact PI/PD** (multi PD/PI with Christopher McFarland, Case Western University), for “Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC,” R01 CA271540 (01/01/23–12/31/27) (year 1 funding, \$541,670).

### Submitted

- **France Carrier, PhD**, collaboration with Columbia University on Administrative Supplements to Existing NIH Grants and Cooperative Agreements, for “Investigating neutron-induced lung injury,” R01 CA271540 (2/2023–5/2023) (\$98,347).

## Articles Published

Entered into PubMed December 7–January 11. Titles link to PubMed abstracts, with full-text links.

1. **Becker SJ**, Lipson EJ, Jozsef G, **Molitoris JK**, Silverman JS, Presser J, Kondziolka D. [How many brain metastases can be treated with stereotactic radiosurgery before the radiation dose delivered to normal brain tissue rivals that associated with standard whole brain radiotherapy?](#) *J Appl Clin Med Phys*. 2023 Jan 11:e13856. Online ahead of print.
2. **Cao Y, Kunaprayoon D, Xu J, Ren L**. [AI-assisted clinical decision making \(CDM\) for dose prescription in radiosurgery of brain metastases using three-path three-dimensional CNN](#). *Clin Transl Radiat Oncol*. 2022 Dec 20;39:100565.
3. Coburn KM, Roth B, Varney KM, **Carrier F**, Weber DJ. [<sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N assignments of the mRNA binding protein hnRNP A18](#). *Biomol NMR Assign*. 2022 Dec 21. Online ahead of print.
4. **Jiang K, MacFarlane M, Mossahebi S, Zakhary MJ**. [Evaluation of treatment planning system accuracy in estimating the stopping-power ratio of immobilization devices for proton therapy](#). *J Appl Clin Med Phys*. 2023 Jan 2:e13831. Online ahead of print.
5. McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M 3rd, Dess R, **Mishra MV**, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. [Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126](#). *Cancer*. 2022 Dec 29. Online ahead of print.
6. **Molitoris JK**. [Start combining, stop comparing](#). *Int J Radiat Oncol Biol Phys*. 2023 Feb 1;115(2):279.
7. Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M 3rd, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, **Tran P**, Feng FY. [Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials](#). *Int J Radiat Oncol Biol Phys*. 2022 Dec 31:S0360-3016(22)03688-4. Online ahead of print.
8. Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, Haustermans K, Hölscher T, Höcht S, Ghadjar P, Davicioni E, Heck M, Kerkmeijer LGW, Kirste S, Tselis N, **Tran PT**, Pinkawa M, Pommier P, Deltas C, Schmidt-Hegemann NS, Wiegel T, Zilli T, Tree AC, Qiu X, Murthy V, Epstein JI, Graztke C, Gao X, Grosu AL, Kamran SC, Zamboglou C. [Genomic classifiers in personalized prostate cancer radiotherapy approaches—a systematic review and future perspectives based on international consensus](#). *Int J Radiat Oncol Biol Phys*. 2022 Dec 31:S0360-3016(22)03691-4. Online ahead of print.
9. Ward MC, Fasola CE, White RL Jr, **Bentzen SM**, Khan AJ, Vicini F, Shah C. [In regard to Vaidya et al](#). *Int J Radiat Oncol Biol Phys*. 2023 Jan 1;115(1):255–256.

## Important Dates for Upcoming Funding Submissions

Below is an updated calendar with firm due dates for upcoming major NIH deadlines (individual RFA/PA dates may differ). Contact the Department Office of Research Administration (DORA) ([msegers@som.umaryland.edu](mailto:msegers@som.umaryland.edu)) ASAP if you plan to submit any funding proposal, regardless of funder. Failure to meet these deadlines may result in delaying your submission until the next cycle (if available).

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01 new sub. 02/06/23	01/23/23	01/26/23	01/30/23
R21 new sub. 02/16/23	02/02/23	02/06/23	02/09/23
R01 Resub. 03/05/23	02/21/23	02/23/23	02/27/23
R21 Resub. 03/16/23	03/03/23	03/07/23	03/09/23